AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

by Barry101 | Dec 12, 2024 | Press Release

OCALA, Fla., Dec. 12, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 – a compositions and...

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell

by Barry101 | Dec 10, 2024 | Press Release

Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Conclude That Activist Group’s Plan Lacks Detail and Does Not Justify Control of the Board ISS and Glass Lewis Both Recommend Against the Election of Activist Group Nominees Todd...

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

by Barry101 | Dec 6, 2024 | Press Release

Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced...

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell

by Barry101 | Dec 5, 2024 | Press Release

ISS Finds That Activist Group’s Plan is “Limited” and Does Not Justify Control of the Board ISS Notes Activist Group Nominee Robert L. Chioini “Does Not Appear to Be an Appropriate Choice for the AIM Board” Given His Track Record at...

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board

by Barry101 | Dec 2, 2024 | Press Release

Highlights Activist Group’s Nominees’ Checkered Backgrounds, Skewed Incentives and Lack of Independence Warns AIM Shareholders of Activist Group’s Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to...